Please join our upcoming webinar with Dr. Stephen Brunton, MD, FAAFP, CDCES on Wednesday, September 20, at 5:30pm-6:15pm ET, entitled, The Future of Renal Health in Type 2 Diabetes: The Urgency of Early-Stage Chronic Kidney Disease Detection and Intervention. Register today!

Clinicians are faced with significant challenges when it comes to the complex management needs of patients with chronic diseases, including diabetic kidney disease (DKD). Until recently, treatment options for DKD were limited. Large-scale clinical trials have demonstrated that novel therapeutics, like SGLT2i's, can significantly slow the progression of kidney disease by 25% and reduce the risk of cardiovascular events, heart failure and death.

The future of renal health involves the use of prognostic tests such as KidneyIntelX, in which clinicians can simply and accurately identify those adult patients with type 2 diabetes and early-stage CKD who are at the highest risk for rapid decline in kidney function, including kidney dialysis and kidney failure. Implementation of prognostic tests such as KidneyIntelX in the primary care setting will enable clinicians to optimize the therapeutic management and specialist referrals of patients with early-stage DKD, thus avoiding the downstream health consequences of kidney disease.

Chronic kidney disease is recognized as a growing epidemic affecting 850 million worldwide and 38 million in the United States. African Americans have the highest incidence of end-stage kidney disease.

Please join us to:

• Understand the epidemiology and the burden of diabetic kidney disease in the U.S.
• Identify clinical opportunities to improve patient outcomes and reduce the burden of kidney disease.
• Learn how risk assessment tools can reduce complexity in clinical practice.
• Discuss patient case studies and outcomes.

KidneyIntelX™ is a blood test intended for adult patients with type 2 diabetes in early-stage chronic kidney disease that identifies patients at highest risk for rapid decline in kidney function, including end stage kidney disease (kidney failure). The test combines three biomarkers associated with subclinical inflammation and kidney injury with other clinical features into a machine-learning algorithm that risk stratifies patients into low, intermediate and high risk. Knowing who is at highest risk early in their "CKD journey" allows clinicians to take guideline-recommended actions early when it matters most.

Register here